With two FDA-approved therapies now available for MASH with moderate to advanced fibrosis, FibroScan® helps connect patients to treatment by enabling early diagnosis, risk stratification, and ongoing monitoring.
For the first time, adults with noncirrhotic MASH and moderate to advanced fibrosis (F2–F3) have access to two FDA-approved medications. Rezdiffra™ (resmetirom) was the first drug approved for this indication, in March 2024, followed by Wegovy® (semaglutide), in August 2025, a GLP-1 therapy also indicated for weight management and cardiovascular risk reduction. These approvals mark a major turning point in liver health, creating new urgency around early identification and accurate assessment—areas where FibroScan® delivers unique value. |
Rezdiffra™ is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Wegovy® (semaglutide) injection 2.4 mg is indicated, in combination with a reduced calorie diet and increased physical activity, for:
Please see full prescribing information for Rezdiffra™ and Wegovy®.
|
FibroScan® is widely adopted in clinical practice and has been instrumental in the pivotal trials that led to the recent FDA approvals for MASH therapies.
MASH affects approximately 1 in 20 adults1, yet 9 out of 10 people2 living with it remain undiagnosed.
Without intervention, MASH can progress to cirrhosis, liver failure, and higher risk of cardiovascular events and type 2 diabetes.
Expanding access to scalable, validated, and cost-effective NITs like FibroScan® is critical to closing the diagnosis gap and connecting patients with timely care.
Discover how FibroScan® can support diagnosis, streamline documentation, and help your team monitor patient response to new MASH therapies.